Phaseline

Companies › Third Arc Bio

Third Arc Bio: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout May 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ARC101–Phase 1Advanced Solid TumorMay 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06672185ARC101Phase 1Advanced Solid TumorOncologyMay 2028

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.